Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for episodic cluster headache (randomized double-blind placebo-controlled delayed-start study)
2020-001969-37Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cluster Headache (CH) comparing Eptinezumab with Placebo → delayed-start eptinezumab (2 arms). Primary endpoint: Change from baseline in number of weekly attacks. Started Dec 2020; status: terminated.
02
Drugs
eptinezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2020-001969-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001969-37.